SCHEMBL5453475

SCHEMBL5453475

NC(=O)c1c(NC(=O)Nc2ccc(C(F)(F)F)cc2)sc2c1CCCC2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 2/20 0.65
TLR2 O60603 2/20 0.61
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
ALDH1A1 P00352 4/20 0.61
MAPT P10636 3/20 0.61
GAA P10253 2/20 0.61
FLT3 P36888 8/20 0.59
NPC1 O15118 6/20 0.58
RAB9A P51151 6/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
LMNA P02545 2/20 0.57
POLB P06746 1/20 0.57
CYP1A2 P05177 1/20 0.55
CYP2C19 P33261 1/20 0.55
CASP3 P42574 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
KCNH2 Q12809 1/20 0.54
KDM4E B2RXH2 1/20 0.54
ESR1 P03372 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458235 0.89 FLT3 (0.55) ANO1MEN1KMT2AALDH1A1MAPT
SCHEMBL5455065 0.87 MEN1 (0.79) ANO1TLR2MEN1KMT2AALDH1A1
SCHEMBL5467447 0.87 MAPT (0.56) ANO1MEN1KMT2AALDH1A1MAPT
SCHEMBL8289498 0.86 FLT3 (0.79) MEN1KMT2AALDH1A1MAPTFLT3
SCHEMBL4234573 0.86 FLT3 (0.72) ANO1MEN1KMT2AALDH1A1MAPT
SCHEMBL5455812 0.86 MAPT (0.58) ANO1TLR2MEN1KMT2AALDH1A1
SCHEMBL5453526 0.86 KCNH2 (0.52) ANO1TLR2MEN1KMT2AALDH1A1
SCHEMBL5454155 0.86 KCNH2 (0.49) ANO1TLR2MEN1KMT2AALDH1A1
SCHEMBL8288685 0.85 FLT3 (0.77) ANO1MEN1KMT2AALDH1A1MAPT
SCHEMBL5447523 0.85 CFTR (0.56) ANO1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 ANO1 3245/4885TLR2 3061/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.